• Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa

      Taylor, WR; Naw, HK; Maitland, K; Williams, TN; Kapulu, M; D'Alessandro, U; Berkley, JA; Bejon, P; Okebe, J; Achan, J; Amambua, AN; Affara, M; Nwakanma, D; van Geertruyden, JP; Mavoko, M; Lutumba, P; Matangila, J; Brasseur, P; Piola, P; Randremanana, R; Lasry, E; Fanello, C; Onyamboko, M; Schramm, B; Yah, Z; Jones, J; Fairhurst, RM; Diakite, M; Malenga, G; Molyneux, M; Rwagacondo, C; Obonyo, C; Gadisa, E; Aseffa, A; Loolpapit, M; Henry, MC; Dorsey, G; John, C; Sirima, SB; Barnes, KI; Kremsner, P; Day, NP; White, NJ; Mukaka, M (BioMed Central, 2018-01-18)
      In 2012, the World Health Organization recommended blocking the transmission of Plasmodium falciparum with single low-dose primaquine (SLDPQ, target dose 0.25 mg base/kg body weight), without testing for glucose-6-phosphate dehydrogenase deficiency (G6PDd), when treating patients with uncomplicated falciparum malaria. We sought to develop an age-based SLDPQ regimen that would be suitable for sub-Saharan Africa.